ISAR Research Updates
Research topic prioritized by the ISAR steering committee for the second year 2019:
Comparative effectiveness across severe asthma biologic classes (Anti-IL5 vs Anti lgE) in patients eligible for both modalities.
Aim:
– To identify ISAR patients who are eligible for both Anti-IL5 and Anti-IgE
– Describe and compare clinical outcomes across patients receiving two classes of biologics: Asthma Control, Exacerbations, Lung Function, HRU
Following research topics were prioritized during the ISC Closed session for 2019 and are open to researchers to join and lead. Submit your interest through our website or contact your country lead for further details.
Research Topic |
Describe the OCS landscape: annual consumption, prevalence, outcomes and side effects of long-term OCS users |
Outcomes of switching between Anti-IL5 receptor α chain monoclonal antibody and Anti-IL5 monoclonal antibody therapy in severe asthma |
Characterization of health disparities (burden of illness or mortality) across countries |
Criteria for choosing and switching between similar biological treatment options in patients with atopic and non-atopic severe eosinophilic asthma |
Research topic prioritized by the ISAR steering committee for the second year 2018:
The Characterization and Comparison of Eosinophilic and Non-eosinophilic Phenotypes of Severe Asthma
Aim: To describe and compare the demographic and clinical features of the eosinophilic versus non-eosinophilic severe asthma phenotypes and to investigate the unique clusters of asthma phenotypes in the ISAR.
Group characterization and feasibility numbers were presented at the REG summit 2019 during the ISAR Research Collaborator Meeting.
Research Topic | Project Lead | Aim |
Biologics in Severe Asthma: Utilization Patterns, Causes for Discontinuation and Switching and Adverse Outcomes* | Dr. Andrew Menzies-Gow (UK) | ·To describe the cohort of severe asthma patients that switch biologics and to investigate their incidence of anaphylaxis and serious infections |
Hidden Severe Asthma Patients in Primary Care vs. ISAR Cohort* | Prof. David Price (Singapore) | ·To identify the extent of “hidden” severe asthma patients in primary care setting using a large, real-life population-based cohort of asthma patients in the UK, and potentially other countries, such as Denmark, France and South Korea. ·To compare the “hidden” severe asthma patients identified in primary care to t those managed in specialist care in terms of demographic and clinical characteristics. |
The Impact of Exacerbation Burden on Lung Function Trajectory in a Broad Asthma Population and Severe Asthma Population* | Prof. Liam Heaney (UK) | ·To examine the relationship between exacerbation burden and lung function trajectories and to explore an optimal time for a therapeutic intervention to prevent excess lung function decline |
Assess the Overlap of Collected Biomarkers* | Dr. Eve Denton & Dr. Mark Hew (Australia) | ·To assess biomarker relatability and their independent and/or combined ability to inform about severe asthma patients |
Identify Predictors (e.g. biomarkers) of Response to Biologics | Dr. Eve Denton & Dr. Mark Hew (Australia) | ·To identify independent predictors of no/partial/high clinical response to biologic therapy ·To evaluate baseline biomarkers that predict a response to biologics |
Hidden Chronic Asthma within the COPD/ACO Population | Dr. Chin Kook Rhee (Korea) | ·To identify hidden & treatable severe asthma population within a global cohort of COPD or ACO |
Onset of Asthma in Severe Asthma patients | Dr. Enrico Heffler (Italy) | ·To distinguish severe asthma phenotypes by asthma-onset |
*Note: Funded Studies
Research topic prioritized by the ISAR steering committee for the inaugural year 2017:
Demographic and Clinical Characteristics of Severe Asthma Patients Worldwide
Aim: To describe and compare the demographic and clinical characteristics of the severe asthma population globally
Characteristics described: Demographic distribution, Medication, Comorbidities, Asthma Control, Eosinophils, and IgE counts, Lung Function, Healthcare Resource Utilization, etc.
4,990 patients from five countries have contributed to this first research project of ISAR.